Coverage
AstraZeneca PLC said its experimental drug baxdrostat significantly lowered blood pressure in patients with a hard-to-treat form of hypertension, meeting the main goal of a late-stage trial.
AstraZeneca PLC and Daiichi Sankyo said their drug Datroway significantly improved survival for patients with an aggressive form of breast cancer in a late-stage study.
AstraZeneca PLC said its cancer drug Enhertu, developed with Daiichi Sankyo, showed a significant improvement over the standard treatment in a late-stage trial for patients with a high-risk form of early breast cancer.
AstraZeneca PLC on Monday announced plans to directly list its ordinary shares on the New York Stock Exchange, a move aimed at attracting a broader base of global investors and accessing deeper capital pools.
AstraZeneca PLC said its drug Koselugo won a key European regulatory backing for use in adults, a positive development for the company following recent setbacks in its drug pipeline.
AstraZeneca PLC said its drug Tezspire, developed with Amgen Inc., won a key European regulatory backing for a new use, a positive development for the company following recent trial setbacks.
Filings
| Filing | Date |
|---|---|
| Baxdrostat met primary endpoint in Bax24 Ph3 trial | 7 Oct 2025 |
| Datroway improved OS and PFS in TROPION-Breast02 | 6 Oct 2025 |
| Total Voting Rights | 1 Oct 2025 |
| Enhertu improved IDFS in early BC in DB-05 | 29 Sept 2025 |
| AZN harmonises listing structure | 29 Sept 2025 |
| Director/PDMR Shareholding | 25 Sept 2025 |
| Koselugo recommended for EU approval | 22 Sept 2025 |
| Tezspire Recommended for Approval in EU for CRSwNP | 22 Sept 2025 |
| Saphnelo met primary endpoint in TULIP-SC | 17 Sept 2025 |
| Update on RESOLUTE Phase III trial | 17 Sept 2025 |
| Total Voting Rights | 1 Sept 2025 |
| Holding(s) in Company | 28 Aug 2025 |